Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up
In Vivo · 2025
DOI: 10.21873/invivo.13833 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Risa Nishiyama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan risanishiyama2353@gmail.co…. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Melphalan, Transplantation Conditioning. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan risanishiyama2353@gmail.com.
- Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Zitieren
APA
Nishiyama, R., Kagoo, T., Ueno, H., & Yokoyama, A. (2025). Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up. In Vivo. https://doi.org/10.21873/invivo.13833
Vancouver
Nishiyama R, Kagoo T, Ueno H, Yokoyama A. Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up. In Vivo. 2025. doi:10.21873/invivo.13833
BibTeX
@article{Nishiyama2025,
author = {Nishiyama, Risa and Kagoo, Toshiya and Ueno, Hironori and Yokoyama, Akihiro},
title = {Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.13833}
}
EUVIMED